MarketPulse

chronic low back pain

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Hits $30.3M Ryoncil Revenue as Cash Burn Slows to $4.1M

Mesoblast reports Q3 FY2026 Ryoncil revenues of $30.3M, approaching $100M cumulative sales, while reducing operating cash spend and strengthening balance sheet.
MESOFDA approvalrevenue growth
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Mesoblast Hits Recruitment Milestone in Pivotal Back Pain Trial

Mesoblast completes recruitment of 300+ patients in pivotal Phase 3 trial for chronic back pain therapy, targeting mid-2027 results and Q3 2027 FDA filing.
MESOPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aclarion Taps Veteran Medical Device Executive to Expand Nociscan in Western U.S.

Aclarion appoints Daniel Keefe as Western U.S. Commercial Director to accelerate adoption of its Nociscan diagnostic platform amid triple-digit growth.
ACONACONWchronic low back painbiomarkers
GlobeNewswire Inc.GlobeNewswire Inc.··Aclarion, Inc.

Aclarion Charts Path to Growth With 2026 Reimbursement Push and Clinical Readouts

Aclarion outlines 2026 priorities: pursuing regional insurance reimbursement, releasing CLARITY trial results in Q4 2026, and expanding Nociscan adoption. Strong balance sheet extends to 2028.
ACONACONWbalance sheetchronic low back pain
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aclarion Positions for Growth With Debt-Free Balance Sheet Ahead of ROTH Conference

Aclarion to present at ROTH Conference with debt-free balance sheet, outlining 2026 catalysts for Nociscan expansion in UK and US markets.
ACONACONWbalance sheetchronic low back pain
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Aclarion CEO to Showcase NOCISCAN Platform at LSI USA 2026 Conference

Aclarion CEO to present NOCISCAN platform at LSI USA 2026 investor conference, advancing AI-powered diagnostic technology for chronic low back pain identification.
ACONACONWchronic low back painhealthcare technology
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Posts Strong H1 Results on Ryoncil® Commercial Traction

Mesoblast reports strong H1 results with Ryoncil® revenue of $51.3M and narrowed net losses. Commercial expansion underway with 49 transplant centers operational and FY2026 guidance of $110-120M revenue.
MESOfinancial resultsFDA approval